Axsome Therapeutics Inc. (AXSM)
NASDAQ:AXSM
Want to see AXSM full AI Analyst Report?
AXSM Stock Chart & Stats
$188.99
-$0.23(-0.27%)
At close: 4:00 PM EST
$188.99
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$96.09 - $260.19
Previous CloseN/A
Volume140.83K
Average Volume (3M)667.81K
Market Cap
$12.44B
Enterprise Value$12.89B
Total Cash (Recent Filing)$305.11M
Total Debt (Recent Filing)$219.90M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 10, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding51,459,766
10 Day Avg. Volume715,858
30 Day Avg. Volume667,807
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)102.90
Price to Sales (P/S)14.23
P/FCF Ratio-96.78
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue18.20
Enterprise Value/Gross Profit19.66
Enterprise Value/Ebitda-74.64
Forecast
1Y Price Target
$266.69Price Target Upside41.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$983.55M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Scale With High Gross MarginsSustained, rapid top-line growth combined with very high gross margins indicates durable product economics. High gross margins mean incremental sales flow through to cover fixed costs, enabling operating leverage as AUVELITY and SUNOSI scale and supporting long-term profitability once SG&A and R&D normalize.
AUVELITY First-in-class FDA ApprovalA first-in-class FDA approval in a high-unmet-need indication materially expands AUVELITY's addressable market and prescriber rationale. This durable regulatory foothold supports broader adoption, payer coverage, and the company's upgraded ~$8B peak sales thesis, strengthening long-term commercial upside.
SUNOSI Long-term U.S. Exclusivity SecuredResolving all SUNOSI patent litigation and locking a defined generic entry date through 2040 removes legal overhang and creates multi-year exclusivity. That clarity improves long-term revenue visibility from an established product and reduces the structural risk of near-term generic erosion.
Bears Say
Persistent Cash Burn And Negative FCFNegative operating and free cash flow indicate ongoing cash burn driven by commercialization and R&D. Even with improving trends, the company remains reliant on external funding or rapid margin improvement; this structural cash deficit constrains flexibility and risks dilution if growth or approvals slip.
Elevated Leverage And Thin Equity BaseHigh leverage relative to a small equity base reduces financial resilience. With significant debt outstanding while operations are cash-negative, refinancing and interest obligations heighten execution risk, making the company more vulnerable to adverse outcomes or delayed commercial milestones.
High Gross-to-net And Rising SG&AMaterial gross-to-net discounts materially reduce realized revenue despite strong list sales, and a sharp SG&A ramp to support launches raises the cash burn profile. Together these structural pressures compress margins, prolong break-even timing, and require sustained payer/access gains to realize the underlying economics.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc.’s price range in the past 12 months?
Axsome Therapeutics Inc. lowest stock price was $96.09 and its highest was $260.19 in the past 12 months.
What is Axsome Therapeutics Inc.’s market cap?
Axsome Therapeutics Inc.’s market cap is $12.44B.
When is Axsome Therapeutics Inc.’s upcoming earnings report date?
Axsome Therapeutics Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 43 days.
How were Axsome Therapeutics Inc.’s earnings last quarter?
Axsome Therapeutics Inc. released its earnings results on May 04, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.844 by -$0.416.
Is Axsome Therapeutics Inc. overvalued?
According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued.
Does Axsome Therapeutics Inc. pay dividends?
Axsome Therapeutics Inc. does not currently pay dividends.
What is Axsome Therapeutics Inc.’s EPS estimate?
Axsome Therapeutics Inc.’s EPS estimate is -0.86.
How many shares outstanding does Axsome Therapeutics Inc. have?
Axsome Therapeutics Inc. has 51,459,766 shares outstanding.
What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?
Axsome Therapeutics Inc. reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.844. Following the earnings report the stock price went up 8.314%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.69 (41.11% Upside)
$266.69 (41.11% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 92.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.61%
12-Months-Change
Fundamentals
Return on Equity
-260.01%
Trailing 12-Months
Asset Growth
19.60%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$266.69
▲(41.11% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
15.35% Insiders
25.10% Mutual Funds
20.88% Other Institutional Investors
24.57% Public Companies and Individual Investors